Cyclacel Limited
Private Limited Company · Slough
Creditors Voluntary Liquidation (CVL)United KingdomIncorporated 1996Private Limited Company
Documents & history
Available account evidence and business events. This is not a complete filing history or document library.
Accounts to 2023-12-31
IXBRL · 292 source facts · 26 selected values
Not assessedlegacy record
Accounts to 2023-12-31
IXBRL · 292 source facts · 26 selected values
Not assessed
legacy record
- Reporting period
- 2023-01-01 to 2023-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 199
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2023-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2466_03237549_20231231
- Source archive
- Accounts_Monthly_Data-August2024.zip
Accounts to 2022-12-31
IXBRL · 297 source facts · 29 selected values
Not assessedlegacy record
Accounts to 2022-12-31
IXBRL · 297 source facts · 29 selected values
Not assessed
legacy record
- Reporting period
- 2022-01-01 to 2022-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 208
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0024_03237549_20221231
- Source archive
- Accounts_Monthly_Data-August2023.zip
Accounts to 2021-12-31
IXBRL · 340 source facts · 22 selected values
Not assessedlegacy record
Accounts to 2021-12-31
IXBRL · 340 source facts · 22 selected values
Not assessed
legacy record
- Reporting period
- 2021-01-01 to 2021-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 246
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0109_03237549_20211231
- Source archive
- Accounts_Monthly_Data-August2022.zip
Accounts to 2020-12-31
IXBRL · 353 source facts · 22 selected values
Not assessedlegacy record
Accounts to 2020-12-31
IXBRL · 353 source facts · 22 selected values
Not assessed
legacy record
- Reporting period
- 2020-01-01 to 2020-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 257
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2019-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0089_03237549_20201231
- Source archive
- Accounts_Monthly_Data-April2021.zip
Accounts to 2019-12-31
IXBRL · 324 source facts · 22 selected values
Not assessedlegacy record
Accounts to 2019-12-31
IXBRL · 324 source facts · 22 selected values
Not assessed
legacy record
- Reporting period
- 2019-01-01 to 2019-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 229
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2019-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0084_03237549_20191231
- Source archive
- Accounts_Monthly_Data-November2020.zip
Registered details
03237549- Status
- Liquidation
- Type
- Private Limited Company
- Incorporated
- 1996-08-13
- Jurisdiction
- —
- Registered office
- HERSCHEL HOUSE, 58 HERSCHEL STREET, SLOUGH, BERKSHIRE, SL1 1PG
Classification
1 SIC codes23112
Capital & company events
Reconstructed equity rounds and matched research funding.
Equity fundraising
0 SH01-derived roundsNo reconstructed allotment rounds.
Research and innovation
4 matched grantsMICA: Targeting the RA synovial fibroblast via cyclin dependent kinase inhibition - a phase IIa studyMRC · Research Grant · 2014-03-01 – 2023-12-31 · with 16 other participants£1,311,800whole project
MICA: Targeting the RA synovial fibroblast via cyclin dependent kinase inhibition - a phase IIa study
MRC · Research Grant · 2014-03-01 – 2023-12-31 · with 16 other participants
£1,311,800
whole project
Newcastle UniversityleadArthritis UKCardiff UniversityCatholic University of the Sacred HeartCyclacel LtdCyclacel Ltd - ScotlandHyundai PharmKing'S College LondonRigshospitaletUniversity College LondonUniversity Hospitals Bristol And Weston NHS Foundation TrustUniversity Of BirminghamUniversity of BristolUniversity of CopenhagenUniversity of GlasgowUniversity of LiverpoolUniversity Of Oxford
'First-In-Human' directed pre-clinical development of anti-cancer agent CYC140Lead
Innovate UK · Collaborative R&D · 2013-12-01 – 2016-11-30
£2,264,482
awarded
'First-In-Man' directed pre-clinical development of an anti-cancer agent - CYC065Lead
Innovate UK · Collaborative R&D · 2013-01-01 – 2015-12-31
£1,162,696
awarded
Assessment of CYC065 as a single agent in patients with relapsed/refractory AMLLeadInnovate UK · Collaborative R&D · with 2 other participants
Assessment of CYC065 as a single agent in patients with relapsed/refractory AMLLead
Innovate UK · Collaborative R&D · with 2 other participants